Westlake Biopartners
ActiveFiled to raiseWestlake Village, CABiotech & pharma, Medical devices, Digital healthLast fund filed 2023
4 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Westlake BioPartners Fund IIIFiled to raise in 2023, with no closing reported yet. | 2023 | $450M | $0 | 0 |
| Westlake BioPartners Opportunity Fund I | July 2020 | $100M | $100M | 25 |
| Westlake BioPartners Fund IIFiled to raise in 2020, with no closing reported yet. | 2020 | $450M | $0 | 0 |
| Westlake BioPartners Fund I | August 2018 | $320M | $320M | 33 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 4 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Beth Seidenberg | Selective | Biotech & pharma, Digital health, Medical devices | 21 |
Categories of Westlake Biopartners’s own portfolio companies, based on 31 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Kleiner Perkins | 20 | 3-V Biosciences, Arsenal Biosciences, Auxogyn, BREATHE TECHNOLOGIES, Breathe Technologies, Cell Design Labs, Flexus Biosciences, Hixme Insurance Solutions, KINSA, Latigo Biotherapeutics, Livongo Health, Nina Biotherapeutics, Pinta Biotherapeutics, Practice Fusion, REDBRICK HEALTH, Santa Maria Biotherapeutics, Star Therapeutics, TESARO, Tmunity Therapeutics, Vera Therapeutics |
| NEA | 3 | 3-V Biosciences, Ceterix Orthopaedics, TESARO |
| Venbio Global Strategic | 3 | Arpeggio Biosciences, IMPEL NEUROPHARMA, Neurogastrx |
| 2 |
| David AllisonNot on the current fund | Slowing | Biotech & pharma, Medical devices | 7 | 1 |
| Mira ChaurushiyaNot on the current fund | Slowing | Biotech & pharma | 2 | 1 |
| Peter Calveley | Quiet | None listed | 0 | 0 |
| Scott Ryles | Quiet | None listed | 0 | 0 |
| Sean Harper | Quiet | Fintech, Biotech & pharma | 4 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Westlake Biopartners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Monograph Capital Partners | 2 | Auxogyn, Cell Design Labs |
| Sofinnova Venture Partners | 2 | Star Therapeutics, Vera Therapeutics |
| The Column Group | 2 | Flexus Biosciences, RAPT Therapeutics |
| Vida Ventures | 2 | Auxogyn, Cell Design Labs |
| 7wire Ventures | 1 | Livongo Health |
| Bear Coast | 1 | Livongo Health |
| Builders VC | 1 | Arpeggio Biosciences |
| Camber Creek | 1 | Breathe Technologies |
| Commerce Ventures | 1 | Kin Insurance |
| Cure Ventures | 1 | KINSA |
| Define Ventures | 1 | Livongo Health |
| Entrada Ventures | 1 | RAPT Therapeutics |
A shared board seat: a company where filings name a Westlake Biopartners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.